<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4415">
  <stage>Registered</stage>
  <submitdate>14/01/2013</submitdate>
  <approvaldate>14/01/2013</approvaldate>
  <nctid>NCT01769001</nctid>
  <trial_identification>
    <studytitle>An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients</studytitle>
    <scientifictitle>An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PB-102-F02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Fabry Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PRX-102

Experimental: 1 mg/kg - PRX-102 1 mg/kg every 2 weeks

Experimental: 2 mg/kg - PRX-102 2 mg/kg every 2 weeks

Experimental: 0.2 mg/kg - PRX-102 0.2 mg/kg every 2 weeks


Treatment: drugs: PRX-102
Comparison of different doses of drug

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with adverse events as a measure of safety - Adverse events reported by the patient and from monitoring with clinical laboratory, physical examination, ECG</outcome>
      <timepoint>38 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Gb3 concentrations - Gb3 concentrations in plasma and urine sediment</outcome>
      <timepoint>38 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Glomerular filtration rate - Measurement of glomerular filtration</outcome>
      <timepoint>38 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain - Short term brief pain inventory</outcome>
      <timepoint>38 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proteinuria - Measure of kidney function</outcome>
      <timepoint>38 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Completion of Phase 1/2 study PB-102-F01

          -  The patient signs informed consent

          -  Female patients and male patients whose co-partners are of child-bearing potential
             agree to use a medically acceptable method of contraception, not including the rhythm
             method</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or nursing

          -  Presence of any medical, emotional, behavioral or psychological condition that, in the
             judgment of the Investigator and/or Medical Director, would interfere with the
             patient's compliance with the requirements of the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>18</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Melbourne Hospital - Victoria</hospital>
    <postcode>3050 - Victoria</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Paraguay</country>
      <state>Asuncion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Zaragoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protalix</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients will be enrolled into one of three PRX-102 dosing groups (0.2 mg/kg, 1.0 mg/kg, 2.0
      mg/kg), to receive the same dose they had received in Phase 1/2 study PB-102-F01, and will
      continue to receive PRX-102 as an intravenous infusion every 2 weeks for 38 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01769001</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Einat Almon, PhD</name>
      <address>Protalix Biotherapeutics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>